Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Cinclus Pharma in connection with listing on Nasdaq Stockholm
Mandate

Vinge advises Cinclus Pharma in connection with listing on Nasdaq Stockholm

June 20, 2024 Intellectual Property Capital Markets and Public M&A Corporate Tax Employment and Benefits IT, Telecommunications and Outsourcing Banking and Finance

Vinge advises Cinclus Pharma Holding AB (publ) (“Cinclus Pharma”) in connection with an offering of new ordinary shares and listing on Nasdaq Stockholm. The first day of trading is 20 June 2024.

The offering will provide Cinclus Pharma with proceeds of approximately SEK 787 million before deduction of issue costs and provided that the over-allotment option is fully exercised. In connection with the offering, Cinclus Pharma also carries out a set-off issue at the offering price to convert outstanding bridge loans. 

Cinclus Pharma is a clinical-stage pharmaceutical company focused on the development of the drug candidate linaprazan glurate, a proprietary “prodrug” of the molecule linaprazan. Linaprazan glurate represents a new and innovative mode of action for the treatment of erosive GERD.

Vinge's team mainly consists of Dain Hård Nevonen,Amanda Knutsson, Anna Svensson,Michaela Ådén and Filip Magnusson (Capital Markets and Public M&A), Stojan Arnestål (IP/Life science), Maria Schultzberg (Corporate taxation), Mathilda Persson (Commercial agreements), Gulestan Ali (Compliance), Nicklas Thorgerzon (IT/GDPR), Jonatan Stentorp (Employment) and Sofia Haggren (Financing).

Related

Vinge has advised SBB and Sveafastigheter in connection with an exchange offer

 Vinge has advised Samhällsbyggnadsbolaget i Norden AB (SBB) and Sveafastigheter AB in connection with an exchange offer directed to investors in SBB’s outstanding bonds, whereby investors exchanged senior and hybrid bonds in SBB for new senior bonds issued in Sveafastigheter AB. The existing bonds were partly issued under SBB’s EMTN programme, partly on a standalone basis. Following the transaction, the investors have been slotted in under Swedish bond terms on a standalone basis.
July 09, 2024

Vinge advises Polar Structure AB in connection with its issuance of EUR 81 million senior secured notes through a majority owned subsidiary

 Vinge advises Polar Structure AB, a leading developer and owner of infrastructure, in connection with its issuance of EUR 81 million senior secured notes through a majority owned subsidiary. The proceeds will be used to finance the construction of a railway outside Boden, which will connect the existing iron ore line (Sw. Malmbanan) with H2 Green Steel’s new facility for large-scale production of green steel at Boden Industrial Park.
July 04, 2024

Vinge advises Bergs Timber AB (publ) and Bitus A

 Vinge advises Bergs Timber AB (publ) and Bitus AB in connection with the divestment of the Fågelfors pellets business to J. Rettenmeier & Söhne. The Fågelfors pellets factory is based in Fågelfors in Högsby. The acquisition is subject to customary regulatory approvals.
July 03, 2024